Eisai Co., Ltd (ADR) - ESALY - Financial Statement Analysis

All financial statement analysis reports for your requested company can be accessed below. The SIC # column is the SIC Code for the industry under which the current company is analyzed. When a report is purchased the SIC Code indicated is the industry that the company displayed will be compared against. If a different industry is desired for comparison, purchase of a separate industry analysis is suggested.

In addition to the ratio analysis reports, the latest business news headlines involving your company or industry sector are hyperlinked for your convenience along with the stock ticker for the company displayed.

Financial statement analysis updated: May 19, 2013

Eisai Co., Ltd (ADR) - SIC # 2834

Ticker	Exchange	SIC #	Website	Latest Ticker
ESALY	Over the counter	2834	http://www.eisai.com	43.49 -0.15
Select one of the five (5) financial statement analysis reports below to view the ratio analysis report for your selected company: Publicly Traded Company Industry Ratios Publicly Traded Company VS. Industry Ratios Publicly Traded Company VS Publicly Traded Company Private Company VS Publicly Traded Company
Latest Headlines for Eisai Co., Ltd (ADR) The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does - May 21st, 2013 4:56 am Arena Outlines Belviq Launch And Goals - May 17th, 2013 12:01 am Jazz Pharma Posts Higher Y/Y Earnings - May 14th, 2013 8:20 am Barron's 500: America's Top Companies Leave One Wishing For A Thicker Wallet - May 7th, 2013 4:29 am Arena Pharma Narrows Loss - May 6th, 2013 8:40 am Ahead of the Bell: Arena Pharma price targets fall - May 3rd, 2013 5:33 am Ahead of the Bell: Arena Pharma price targets fall - May 3rd, 2013 5:33 am Arena shares plunge after disappointing 1Q results - May 2nd, 2013 3:59 pm Arena shares plunge after disappointing 1Q results - May 2nd, 2013 3:24 pm Arena Faces A Convergence Of DEA And European Decisions - Apr 24th, 2013 3:47 am Data from Novartis' SPARK - Apr 23rd, 2013 3:15 pm BioLineRx to Start BL-8040 Study - Apr 16th, 2013 4:00 pm Eisai Announces Preclinical Research Findings Suggesting Novel Infibitory Effect on Tumor Metastasis for Anticancer Agent Halaven(R) at AACR 104th Annual Meeting - Apr 10th, 2013 6:57 am Patients Dosed in Arena Study - Apr 9th, 2013 3:25 pm Eisai Co-establishes the Global Health Innovative Technology Fund - Apr 8th, 2013 3:48 am As Arena Pharma Begins To Address Mexican Obesity, All Eyes Are Now On The DEA - Apr 8th, 2013 3:03 am Eisai Establishes Pharma Sales Subsidiary in Moscow Ahead of Planned Direct Sales Launch in Russia - Apr 5th, 2013 3:20 am Eisai to Launch Botulinum Toxin Type B Neuromuscular-Blocking Agent Nerbloc(R) intramuscular Injection 2500 Units in Japan - Mar 26th, 2013 1:44 am Eisai Recieves Manufacturing and Marketing Authorization for Antiepileptic Agent Inovelon(R) in Japan - Mar 25th, 2013 4:53 am 2 Biotech Stocks With Huge Potential For The Speculative Investor - Mar 14th, 2013 2:51 am View All Current Headlines >>